Patients with high-risk stage III-IV melanoma who received Keytruda (pembrolizumab) after surgery reported a better quality of life than patients who received the previous standard-of-care treatment with either ipilimumab or high-dose interferon, according to a large clinical trial led by the SWOG Cancer Research Network.
In a phase Ib/II clinical trial known as EPCORE NHL-2, a team of researchers—led by Joshua Brody, director of the Lymphoma Immunotherapy Program at the Tisch Cancer Institute at Mount Sinai—showed the benefit of combining chemotherapy with immunotherapy for diffuse large B-cell lymphoma. The results were published earlier this month in the journal Blood.
